Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Arruda

Showing results (61-70 of 185) with videos related to

Pageof 19
Sort By:
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
Blood|November 20, 2004
Factor IX variants improve gene therapy efficacy for hemophilia BJoerg Schuettrumpf, Roland W Herzog, Alexander Schlachterman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2001
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutationR W Herzog, J D Mount, V R Arruda, et al.
Human Mutation|January 1, 1997
G6PD sumaré: a novel mutation in the G6PD gene (1292 T-->G) associated with chronic nonspherocytic anemiaS T Saad, T S Salles, V R Arruda, et al.
Haematologica|December 14, 2004
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s)Christian Furlan Freguia, Raffaella Toso, Eleanor S Pollak, et al.
The Journal of Clinical Investigation|April 2, 2004
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VIIParis Margaritis, Valder R Arruda, Majed Aljamali, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Sao Paulo Medical Journal = Revista Paulista De Medicina|July 1, 1997
Studies on the components of the contact phase system in patients with acute nonlymphoblastic leukemiaJ M Annichino-Bizzacchi, V R Arruda, T F Machado, et al.
Genetics and Molecular Research : GMR|July 11, 2017
An optimized protocol for DNA extraction in plants with a high content of secondary metabolites, based on leaves of Mimosa tenuiflora (Willd.) Poir. (Leguminosae)S R Arruda, D G Pereira, M M Silva-Castro, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 16, 2003
Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patientsDalva N Rodrigues, Lucia H Siqueira, Andréa M Galizoni, et al.
Pageof 19

Showing results (61-70 of 185) with videos related to

Sort By:
Pageof 19
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
Blood|November 20, 2004
Factor IX variants improve gene therapy efficacy for hemophilia BJoerg Schuettrumpf, Roland W Herzog, Alexander Schlachterman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2001
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutationR W Herzog, J D Mount, V R Arruda, et al.
Human Mutation|January 1, 1997
G6PD sumaré: a novel mutation in the G6PD gene (1292 T-->G) associated with chronic nonspherocytic anemiaS T Saad, T S Salles, V R Arruda, et al.
Haematologica|December 14, 2004
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s)Christian Furlan Freguia, Raffaella Toso, Eleanor S Pollak, et al.
The Journal of Clinical Investigation|April 2, 2004
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VIIParis Margaritis, Valder R Arruda, Majed Aljamali, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Sao Paulo Medical Journal = Revista Paulista De Medicina|July 1, 1997
Studies on the components of the contact phase system in patients with acute nonlymphoblastic leukemiaJ M Annichino-Bizzacchi, V R Arruda, T F Machado, et al.
Genetics and Molecular Research : GMR|July 11, 2017
An optimized protocol for DNA extraction in plants with a high content of secondary metabolites, based on leaves of Mimosa tenuiflora (Willd.) Poir. (Leguminosae)S R Arruda, D G Pereira, M M Silva-Castro, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 16, 2003
Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patientsDalva N Rodrigues, Lucia H Siqueira, Andréa M Galizoni, et al.
Pageof 19